Modeling HIV-1 Within-Host Dynamics After Passive Infusion of the Broadly Neutralizing Antibody VRC01

Modeling HIV-1 Within-Host Dynamics After Passive Infusion of the Broadly Neutralizing Antibody VRC01

VRC01 is a broadly neutralizing antibody that targets the CD4 binding site of HIV-1 gp120. Passive administration of VRC01 in humans has assessed the safety and the effect on plasma viremia of this monoclonal antibody (mAb) in a phase 1 clinical trial. After VRC01 infusion, the plasma viral load in...

Full description

Bibliographic Details
Main Authors:	E. Fabian Cardozo-Ojeda, Alan S. Perelson
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2021-08-01
Series:	Frontiers in Immunology
Subjects:	virus dynamics HIV-1 VRC01 mathematical modeling ODE
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2021.710012/full

Similar Items

Differences in Allelic Frequency and CDRH3 Region Limit the Engagement of HIV Env Immunogens by Putative VRC01 Neutralizing Antibody Precursors
by: Christina Yacoob, et al.
Published: (2016-11-01)

Germline VRC01 antibody recognition of a modified clade C HIV-1 envelope trimer and a glycosylated HIV-1 gp120 core
by: Andrew J Borst, et al.
Published: (2018-11-01)

Pharmacokinetics and predicted neutralisation coverage of VRC01 in HIV-uninfected participants of the Antibody Mediated Prevention (AMP) trials
by: Yunda Huang, et al.
Published: (2021-02-01)

Neutralization diversity of HIV-1 Indian subtype C envelopes obtained from cross sectional and followed up individuals against broadly neutralizing monoclonal antibodies having distinct gp120 specificities
by: Ranajoy Mullick, et al.
Published: (2021-05-01)

A matrix of structure-based designs yields improved VRC01-class antibodies for HIV-1 therapy and prevention
by: Young D. Kwon, et al.
Published: (2021-01-01)

Modeling cumulative overall prevention efficacy for the VRC01 phase 2b efficacy trials
by: Yunda Huang, et al.
Published: (2018-09-01)

Análise reticulocitária a partir de buffy coats
by: Leonel Leandro Mendes, et al.
Published: (2022-04-01)

HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies
by: Labranche, CC, et al.
Published: (2018)

HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies.
by: Celia C LaBranche, et al.
Published: (2018-11-01)

Structure-Based Identification of Natural-Product-Derived Compounds with Potential to Inhibit HIV-1 Entry
by: Nneka Ugwu-Korie, et al.
Published: (2023-01-01)

Characterizing the fitness cost of viral escape from the HIV-1 broadly neutralizing monoclonal antibody VRC01
by: Lynch RM, et al.
Published: (2012-09-01)

Correction: HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies.
by: Celia C LaBranche, et al.
Published: (2019-03-01)

Diverse pathways of escape from all well-characterized VRC01-class broadly neutralizing HIV-1 antibodies.
by: Yuka Otsuka, et al.
Published: (2018-08-01)

Vaccine genetics of IGHV1-2 VRC01-class broadly neutralizing antibody precursor naïve human B cells
by: Jeong Hyun Lee, et al.
Published: (2021-09-01)

V5 region in the HIV-1 envelope glycoprotein determines viral sensitivity to the broadly neutralizing monoclonal antibody VRC01
by: Guo D, et al.
Published: (2012-09-01)

Selection of peptide mimics of HIV-1 epitope recognized by neutralizing antibody VRC01.
by: Anton N Chikaev, et al.
Published: (2015-01-01)

Overcoming Steric Restrictions of VRC01 HIV-1 Neutralizing Antibodies through Immunization
by: K. Rachael Parks, et al.
Published: (2019-12-01)

First-in-human immunoPET imaging of HIV-1 infection using 89Zr-labeled VRC01 broadly neutralizing antibody
by: Denis R. Beckford-Vera, et al.
Published: (2022-03-01)

Second generation of pepino mosaic virus vectors: improved stability in tomato and a wide range of reporter genes
by: Fabiola Ruiz-Ramón, et al.
Published: (2019-05-01)

Neutralization profiles of HIV-1 viruses from the VRC01 Antibody Mediated Prevention (AMP) trials.
by: Nonhlanhla N Mkhize, et al.
Published: (2023-06-01)

Adjuvants influence the maturation of VRC01-like antibodies during immunization
by: Maria L. Knudsen, et al.
Published: (2022-11-01)

Prediction of VRC01 neutralization sensitivity by HIV-1 gp160 sequence features.
by: Craig A Magaret, et al.
Published: (2019-04-01)

Improved pharmacokinetics of HIV-neutralizing VRC01-class antibodies achieved by reduction of net positive charge on variable domain
by: Young D. Kwon, et al.
Published: (2023-12-01)

Engineered gp120 immunogens that elicit VRC01-like antibodies by vaccination
by: Mata-Fink, Jordi, et al.
Published: (2013)

Editorial (Issue 01)
by: Ian Blatchford
Published: (2014-03-01)

A Heterologous V-01 or Variant-Matched Bivalent V-01D-351 Booster following Primary Series of Inactivated Vaccine Enhances the Neutralizing Capacity against SARS-CoV-2 Delta and Omicron Strains
by: Zhiren Zhang, et al.
Published: (2022-07-01)

Prediction of serum HIV-1 neutralization titers of VRC01 in HIV-uninfected Antibody Mediated Prevention (AMP) trial participants
by: Yunda Huang, et al.
Published: (2022-01-01)

Artificial Anti-HIV-1 Immunogen Comprising Epitopes of Broadly Neutralizing Antibodies 2F5, 10E8, and a Peptide Mimic of VRC01 Discontinuous Epitope
by: Andrey P. Rudometov, et al.
Published: (2019-08-01)

[0,1] truncated lomax – lomax distribution with properties
by: Jumana Altawil
Published: (2021-03-01)

Informal Institutions and Herders’ Grazing Intensity Reduction Behavior: Evidence from Pastoral Areas in China
by: Lijia Wang, et al.
Published: (2022-08-01)

The Role of the Chloroplast in the Replication of Positive-Sense Single-Stranded Plant RNA Viruses
by: Marta Budziszewska, et al.
Published: (2018-11-01)

Further Characterization of the Bifunctional HIV Entry Inhibitor sCD4-FIT45
by: Alexander Falkenhagen, et al.
Published: (2017-06-01)

VOC 202012/01 Variant Is Effectively Neutralized by Antibodies Produced by Patients Infected before Its Diffusion in Italy
by: Valeria Rondinone, et al.
Published: (2021-02-01)

In Vivo Activity of LCB 01-0699, a Prodrug of LCB 01-0648, against Staphylococcus aureus
by: Sang-Hun Oh, et al.
Published: (2017-11-01)

Comprehensive Prediction of Thermosyphon Characteristics in Reactor Passive Cooling System Simulation Loop FASSIP-01
by: H. Tjahjono
Published: (2017-12-01)

Development of a VRC01-class germline targeting immunogen derived from anti-idiotypic antibodies
by: Emilie Seydoux, et al.
Published: (2021-05-01)

The Bivalent COVID-19 Booster Immunization after Three Doses of Inactivated Vaccine Augments the Neutralizing Antibody Response against Circulating Omicron Sublineages
by: Qiaren He, et al.
Published: (2022-12-01)

Mathematical modeling of impact of eCD4-Ig molecule in control and management of HIV within a host
by: Tae Jin Lee, et al.
Published: (2021-08-01)

Overexpression and Characterization of a Novel Thermostable β-Agarase YM01-3, from Marine Bacterium Catenovulum agarivorans YM01T
by: Fangyuan Cui, et al.
Published: (2014-05-01)

Broadly Neutralizing Antibodies for Influenza: Passive Immunotherapy and Intranasal Vaccination
by: Mrityunjoy Biswas, et al.
Published: (2020-07-01)